Aveanna Healthcare Holdings Inc. reported strong Q3 2026 results, surpassing analyst expectations on both revenue and earnings. The company’s adjusted EBITDA increased by 25% year-over-year, with margins expanding to 14.4%, signaling improved operational efficiency and cash flow. Despite challenges like high debt and reimbursement risks, Aveanna trades at attractive valuation multiples compared to peers. The company’s growth is supported by organic expansion and acquisition synergies, reinforcing its position in the home healthcare market with promising long-term revenue potential.
Following Aveanna Healthcare's strong Q3 2026 results, the stock is trading at USD 12.37 on Pluang as of Nov 13, 2026 04:11 WIB, down 5.54% for the day. The company holds a market cap of $2.86 billion, with a 52-week range between $6.22 and $14.38. Investor interest on Pluang remains fully on the buy side, reflecting confidence despite the recent price dip.
